AngioDynamics (NASDAQ:ANGO) Earns “Buy” Rating from Canaccord Genuity Group

Posted by Brenda Bartman on Oct 9th, 2026

AngioDynamics (NASDAQ:ANGO – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a research note issued to investors on Friday, Benzinga reports. They presently have a $20.00 target price on the medical instruments supplier’s stock. Canaccord Genuity Group’s target price points to a potential upside of 77.54% from the stock’s previous close.

ANGO has been the topic of a number of other reports. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday. HC Wainwright boosted their target price on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Get Our Latest Report on AngioDynamics

AngioDynamics Price Performance

Shares of ANGO stock traded up $0.04 during trading hours on Friday, hitting $11.27. The company had a trading volume of 503,361 shares, compared to its average volume of 497,311. The stock has a market capitalization of $473.69 million, a PE ratio of -12.94 and a beta of 0.30. AngioDynamics has a fifty-two week low of $9.39 and a fifty-two week high of $16.29. The company’s fifty day moving average is $15.39 and its 200 day moving average is $13.11.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities analysts forecast that AngioDynamics will post -0.25 earnings per share for the current year.

Insider Activity at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ANGO. Integrated Wealth Concepts LLC purchased a new position in shares of AngioDynamics during the 2nd quarter worth about $38,000. Corient Private Wealth LP acquired a new position in AngioDynamics during the second quarter worth approximately $134,000. Public Employees Retirement System of Ohio purchased a new position in AngioDynamics during the second quarter worth approximately $64,000. Bank of America Corp DE acquired a new position in shares of AngioDynamics in the 2nd quarter valued at about $4,490,000. Finally, Gallagher Fiduciary Advisors LLC purchased a new position in AngioDynamics in the 2nd quarter worth approximately $589,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

Positive Sentiment: AngioDynamics reported fiscal Q1 revenue of $80.9 million, slightly above consensus, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, led by 13.2% growth in Med Tech sales. Auryon sales rose 14.7% and NanoKnife sales climbed 29.0%. AngioDynamics Fiscal Q1 Results
Positive Sentiment: The company reiterated fiscal 2027 revenue guidance of $336 million to $341 million and EPS guidance of $(0.29) to $(0.24), broadly in line with analyst expectations. Canaccord Genuity reaffirmed its Buy rating and maintained a $20 price target, implying substantial potential upside from the referenced $11.23 price. AngioDynamics Outlook
Neutral Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The appointment brings an experienced medical-technology executive to the company, but the leadership change introduces near-term execution uncertainty and contributed to the weak market reaction. CEO Appointment
Negative Sentiment: Despite improved results, AngioDynamics remains unprofitable, with a reported GAAP net loss and negative margins. The company used $15.3 million in operating cash during the quarter and held $34.0 million in cash at quarter-end, heightening concerns about profitability and liquidity. The unchanged guidance also failed to provide a stronger catalyst after the earnings release.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.